Pathstone Holdings
AMPH icon

Pathstone Holdings’s Amphastar Pharmaceuticals AMPH Stock Holding History

Pathstone Holdings’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,984
Closed -$213K – 2236
2025
Q3 		$213K Buy
+7,984
New +$206K ﹤0.01% 2182
2025
Q2 		– Sell
-10,328
Closed -$300K – 2194
2025
Q1 		$300K Buy
10,328
+634
+7% +$20.2K ﹤0.01% 1936
2024
Q4 		$360K Sell
9,694
-427
-4% -$19.5K ﹤0.01% 1877
2024
Q3 		$491K Buy
10,121
+2,669
+36% +$117K ﹤0.01% 1737
2024
Q2 		$298K Buy
7,452
+1,845
+33% +$76.5K ﹤0.01% 1943
2024
Q1 		$246K Sell
5,607
-76
-1% -$3.92K ﹤0.01% 2039
2023
Q4 		$351K Buy
+5,683
New +$299K ﹤0.01% 1721

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's AMPH Position: Q4 2025 in Review

Pathstone Holdings sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2025, closing a stake of 7,984 shares — an estimated $213K sold.

Pathstone Holdings first reported a position in AMPH in Q4 2023 and held it in 7 quarters. The position peaked at $491K in Q3 2024. 235 funds tracked by Wall St. Rank hold AMPH as of Q4 2025.

  • Pathstone Holdings reported no remaining Amphastar Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Pathstone Holdings sold 7,984 Amphastar Pharmaceuticals shares in Q4 2025, an estimated $213K.
  • Pathstone Holdings first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Pathstone Holdings's Amphastar Pharmaceuticals position peaked at $491K in Q3 2024.
  • 235 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2025.

Based on Pathstone Holdings's 13F filing for Q4 2025, filed 13 Feb 2026.